Archive for 2019

 
There is a preferential diversion of blood flow to the macula following panretinal photocoagulation leading to an improved macular perfusion.

“Improved Macular Capillary Flow on Optical Coherence Tomography Angiography After Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.”

AJO, Vol 206:217-227, October. 2019
Amani A. Fawzi, Alaa E. fayed, Robert A. Linsenmeier, Jing Gao, and Fei Yu

Full Paper: Improved Macular Capillary Flow on Optical Coherence Tomography Angiography After Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.
Download (81K PDF)

 
The management of patients with bothersome vitreous floaters is controversial. The article below examines the treatment options and makes recommendations as to what is needed to evaluate this condition accurately.

“Assessment of Vitreous Structure and Visual Function after Neodymium:Yttrium-Aluminum-Garnet Laser Vitreolysis”

Ophthalmology, Vol 126, Number 11: 1517-1526, Nov. 2019
Justin H. Nguyen, BA, Jeannie Nguyen-Cuu, BA, Fei Yu, PhD, Kenneth M. Yee, BS, Jonathan Mamou, PhD, Ronald H. Silverman, PhD, FARVO, Jeffrey Ketterling, PhD, J. Sebag, MD, FARVO

Full Paper: Assessment of Vitreous Structure and Visual Function after Neodymium:Yttrium-Aluminum-Garnet Laser Vitreolysis
Download (81K PDF)

 
Panretinal photocoagulation in patients with proliferative diabetic retinopathy maintains a more favorable cost utility compared without intravitreal ranibizumab in patients with and with diabetic macular edema given the marginal visual benefit in intravitreal ranibizumab

“Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy”

Journal of VitreoRetinal Diseases 2019, Vol 3(5) 346-353, Sept/Oct 2019
James Lin, MD, Nicolas A. Yannuzzi, MD, Jonathan S. Chang, MD, Jayanth Sridhar, MD and William E. Smiddy, MD

Full Paper: Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy
Download (92K PDF)

Half-dose photodynamic therapy is superior to high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy, regardless of the presence of focal or diffuse leakage on fluorescein

“Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.

Am. J. Ophthalmol 205:1-10, September 2019
Thomas J. Van Rijssen, Elon H.C. Van Dijk, Paula Scholz, Myrte B. Breukink, Rocio Blanco-Garavito, Eric H. Souied, Jan E.E. Keunen, Robet E. MaClaren, Giuseppe Querques, Sascha Fauser, Susan M. Downes, Carel B. Hoyng, and Camiel J.F. Boon

Full Paper: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
Download (113K PDF)

 
Individualized treat and extend TREX-DME trial for DME resulted in significantly fewer injections and yielded visual and anatomic gains comparable to monthly dosing at 2 years.

Decreasing the treatment burden while providing clinically significant visual and anatomic improvements is of paramount importance.

“Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes”

Am. J. Ophthalmol 202:91-99, June 2019
John F. Payne, Charles C. Wykoff, W. Lloyd Clark, Beau B. Bruce, David S. Boyer, and David M. Brown, For the TREX-DME Study Group

Full Paper: Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
Download (346K PDF)